STOCK TITAN
  1. Home
  2. News
  3. INCY

Incyte Genomics Inc - INCY STOCK NEWS

Welcome to our dedicated page for Incyte Genomics news (Ticker: INCY), a resource for investors and traders seeking the latest updates and insights on Incyte Genomics stock.

Incyte Genomics Inc. (Symbol: INCY) is a leading biopharmaceutical company dedicated to the discovery, development, and commercialization of proprietary therapeutics, with a primary focus on oncology. Headquartered in Wilmington, Delaware, Incyte employs over 625 professionals across its management, discovery, clinical development, and commercial teams.

The company’s flagship product, Jakafi, is a groundbreaking treatment for rare blood cancers and graft versus host disease, developed in partnership with Novartis. Incyte has also made significant strides with its other marketed drugs, including Olumiant for rheumatoid arthritis (licensed to Eli Lilly), Iclusig for chronic myeloid leukemia, Pemazyre for cholangiocarcinoma, Tabrecta for lung cancer, and Monjuvi for diffuse large B-cell lymphoma. Additionally, Incyte's first dermatology product, Opzelura, received approval in 2021 for atopic dermatitis and in 2022 for vitiligo.

Incyte’s pipeline includes a wide array of innovative oncology and dermatology programs, demonstrating their commitment to addressing serious unmet medical needs. The company's strategic collaborations with major pharmaceutical firms further support the clinical development and global commercialization of its compounds.

Incyte’s financial health and robust portfolio position it strongly to continue improving patient lives while building sustainable value for its shareholders. For the latest updates on Incyte’s projects and developments, visit their corporate website at www.incyte.com.

News

Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress

Rhea-AI Summary
Incyte announces new data from its dermatology portfolio to be presented at EADV Congress 2023. Abstracts include efficacy and safety results of ruxolitinib cream for vitiligo and atopic dermatitis, as well as baseline characteristics and impact of povorcitinib for hidradenitis suppurativa. Efforts to advance treatment options emphasized.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
conferences
-
News

AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology

Rhea-AI Summary
AbCellera and Incyte enter strategic collaboration to develop therapeutic antibodies in oncology
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.14%
Tags
none
-
News

Incyte to Present at Upcoming Investor Conferences

Rhea-AI Summary
Incyte (Nasdaq:INCY) to present at investor conferences in September.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.14%
Tags
conferences
News

Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

Rhea-AI Summary
INCY: Incyte reports strong Q2'23 financial results with total net product revenues of $827 million, a 25% Y/Y growth. Jakafi net product revenues were $682 million, up 14% Y/Y. Opzelura cream net product revenues were $80 million, up 384% Y/Y. Two pivotal studies in high potential programs met their primary endpoint, driving a bottom end raise of full year guidance to $2.58 - $2.63 billion for FY 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
earnings
-
News

Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma

Rhea-AI Summary
Replimune Group, Inc. (NASDAQ: REPL) and Incyte (NASDAQ: INCY) announced a clinical trial collaboration and supply agreement to study RP1, Replimune’s lead product candidate, in combination with INCB99280, Incyte’s small molecule oral PD-L1 inhibitor. This collaboration aims to explore the use of RP1 in the neoadjuvant setting for cutaneous squamous cell carcinoma (CSCC) and other cancer types. The unique potential of the RPx platform to induce a patient-specific anti-tumor immune response with an off-the-shelf treatment is highlighted, along with the potential to improve patient experience through the combination with Incyte’s oral PD-L1 inhibitor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
clinical trial
-
News

Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

Rhea-AI Summary
Syndax Pharmaceuticals and Incyte announce positive topline data from the AGAVE-201 trial of axatilimab in chronic graft-versus-host disease (GVHD). The trial met its primary endpoint with an overall response rate of 74% at a dose of 0.3 mg/kg administered every two weeks. The data also showed a durable response to treatment, with 60% of patients still responding at one year. Syndax and Incyte intend to file a Biologics License Application (BLA) by year-end 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
clinical trial
News

Incyte Announces Positive Topline Results from Phase 3 Trial Evaluating Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis

Rhea-AI Summary
Incyte (Nasdaq:INCY) announced positive results from its Phase 3 TRuE-AD3 study evaluating ruxolitinib cream in children with atopic dermatitis. The study met its primary endpoint, with more patients achieving treatment success with ruxolitinib cream compared to the control group. The safety profile was consistent with previous data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
clinical trial
-
News

Incyte to Report Second Quarter Financial Results

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.53%
Tags
conferences earnings
-
News

MHRA Grants Marketing Authorisation for Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents

Rhea-AI Summary
Opzelura® (ruxolitinib) cream has been granted marketing authorization by the MHRA for the treatment of non-segmental vitiligo with facial involvement in the UK. The approval is based on Phase 3 data showing improved repigmentation with longer treatment duration. Vitiligo affects around 1 in 100 people in the UK.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.47%
Tags
none
News

LYMPHOMA THERAPY NOW APPROVED FOR AUSTRALIAN PATIENTS With Diffuse Large B-cell Lymphoma

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
none

FAQ

What is the current stock price of Incyte Genomics (INCY)?

The current stock price of Incyte Genomics (INCY) is $71.72 as of November 22, 2024.

What is the market cap of Incyte Genomics (INCY)?

The market cap of Incyte Genomics (INCY) is approximately 13.6B.

What is Incyte Genomics Inc. known for?

Incyte Genomics Inc. is known for its development and commercialization of proprietary therapeutics, primarily focused on oncology and dermatology.

Where is Incyte Genomics Inc. headquartered?

Incyte Genomics Inc. is headquartered in Wilmington, Delaware.

What is Jakafi?

Jakafi is Incyte's lead drug, used to treat rare blood cancers and graft versus host disease, in collaboration with Novartis.

Which drugs has Incyte marketed?

Incyte has marketed drugs including Olumiant for rheumatoid arthritis, Iclusig for chronic myeloid leukemia, Pemazyre for cholangiocarcinoma, Tabrecta for lung cancer, and Monjuvi for diffuse large B-cell lymphoma.

What is Opzelura used for?

Opzelura is Incyte’s first dermatology product, approved for atopic dermatitis in 2021 and for vitiligo in 2022.

Does Incyte collaborate with other pharmaceutical companies?

Yes, Incyte has established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of its compounds.

How many employees work at Incyte?

Incyte employs over 625 professionals.

What is Incyte's vision?

Incyte's vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs.

How can I get more information about Incyte?

More information about Incyte can be found on their corporate website at www.incyte.com.

What areas does Incyte's pipeline cover?

Incyte's pipeline includes a broad array of oncology and dermatology programs.

Stock INCY logo
Incyte Genomics Inc

Nasdaq:INCY

INCY Rankings

#715 Ranked by Market Cap
N/A Ranked by Dividends

INCY Stock Data

13.56B
188.30M
2.04%
97.86%
3.85%
Biotechnology
Services-commercial Physical & Biological Research
Link
United States of America
WILMINGTON